ConductScience.org, home

Trial · NCT02926950

Results by group22

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnits
Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26Placebo + Metformin-0.29Standard Error 0.079percentage of HbA1c
Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26Sotagliflozin 400 mg + Metformin-0.77Standard Error 0.077percentage of HbA1c
Change From Baseline in 2-hour Postprandial Glucose (PPG) Following a Mixed Meal at Week 26Placebo + Metformin-0.930Standard Error 0.2353millimole per liter (mmol/L)
Change From Baseline in 2-hour Postprandial Glucose (PPG) Following a Mixed Meal at Week 26Sotagliflozin 400 mg + Metformin-2.502Standard Error 0.2292millimole per liter (mmol/L)
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26Placebo + Metformin-0.550Standard Error 0.1864mmol/L
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26Sotagliflozin 400 mg + Metformin-1.310Standard Error 0.2089mmol/L
Change From Baseline in Body Weight at Week 26Placebo + Metformin-0.69Standard Error 0.310kilogram (kg)
Change From Baseline in Body Weight at Week 26Sotagliflozin 400 mg + Metformin-2.56Standard Error 0.331kilogram (kg)
Change From Baseline in Systolic Blood Pressure (SBP) at Week 12 in Participants With Baseline SBP ≥130 mmHgPlacebo + Metformin-6.92Standard Error 1.233millimeter of mercury (mmHg)
Change From Baseline in Systolic Blood Pressure (SBP) at Week 12 in Participants With Baseline SBP ≥130 mmHgSotagliflozin 400 mg + Metformin-10.21Standard Error 1.270millimeter of mercury (mmHg)
Change From Baseline in SBP at Week 12 for All ParticipantsPlacebo + Metformin-1.87Standard Error 0.949mmHg
Change From Baseline in SBP at Week 12 for All ParticipantsSotagliflozin 400 mg + Metformin-5.41Standard Error 0.950mmHg
Percentage of Participants With HbA1c <6.5% at Week 26Placebo + Metformin5.4percentage of participants
Percentage of Participants With HbA1c <6.5% at Week 26Sotagliflozin 400 mg + Metformin10.8percentage of participants
Percentage of Participants With HbA1c <7.0% at Week 26Placebo + Metformin15.8percentage of participants
Percentage of Participants With HbA1c <7.0% at Week 26Sotagliflozin 400 mg + Metformin29.7percentage of participants
Percentage of Participants With Hypoglycemic EventsPlacebo + MetforminAny hypoglycemia11.6percentage of participants
Percentage of Participants With Hypoglycemic EventsSotagliflozin 400 mg + MetforminAny hypoglycemia6.6percentage of participants
Percentage of Participants With Hypoglycemic EventsPlacebo + MetforminDocumented symptomatic hypoglycemia6.2percentage of participants
Percentage of Participants With Hypoglycemic EventsSotagliflozin 400 mg + MetforminDocumented symptomatic hypoglycemia3.1percentage of participants

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02926950/results